Alternative RNA splicing modulates ribosomal composition and determines the spatial phenotype of glioblastoma cells

Larionova et al. identify a mechanism by which acidification of the tumour microenvironment within the glioblastoma core induces the generation of an alternative splice isoform of ribosomal protein RPL22L1, which regulates cell stemness and increases tumour heterogeneity. Glioblastoma (GBM) is characterized by exceptionally high intratumoral heterogeneity. However, the molecular mechanisms underlying the origin of different GBM cell populations remain unclear. Here, we found that the compositions of ribosomes of GBM cells in the tumour core and edge differ due to alternative RNA splicing. The acidic pH in the core switches before messenger RNA splicing of the ribosomal gene RPL22L1 towards the RPL22L1b isoform. This allows cells to survive acidosis, increases stemness and correlates with worse patient outcome. Mechanistically, RPL22L1b promotes RNA splicing by interacting with lncMALAT1 in the nucleus and inducing its degradation. Contrarily, in the tumour edge region, RPL22L1a interacts with ribosomes in the cytoplasm and upregulates the translation of multiple messenger RNAs including TP53. We found that the RPL22L1 isoform switch is regulated by SRSF4 and identified a compound that inhibits this process and decreases tumour growth. These findings demonstrate how distinct GBM cell populations arise during tumour growth. Targeting this mechanism may decrease GBM heterogeneity and facilitate therapy.

Automated summary

Larionova et al. discover a mechanism by which acidification of the tumour microenvironment induces the generation of an alternative splice isoform of ribosomal protein RPL22L1, which regulates cell stemness and increases tumour heterogeneity. The acidic pH in the tumour core switches the RNA splicing of the ribosomal gene towards the RPL22L1b isoform, allowing cells to survive acidosis and promoting stemness. In the tumour edge region, RPL22L1a interacts with ribosomes and upregulates translation of multiple messenger RNAs including TP53. Targeting this mechanism may decrease GBM heterogeneity and facilitate therapy.